DEK is an inclusion criterion in 103 clinical trials for acute myeloid leukemia, of which 60 are open and 43 are closed. Of the trials that contain DEK status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 29 are phase 1 (15 open), 17 are phase 1/phase 2 (12 open), 43 are phase 2 (26 open), 2 are phase 2/phase 3 (1 open), 9 are phase 3 (5 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 66 clinical trials for myelodysplastic syndromes, of which 40 are open and 26 are closed. Of the trials that contain DEK status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 22 are phase 1 (11 open), 9 are phase 1/phase 2 (8 open), 29 are phase 2 (18 open), 1 is phase 2/phase 3 (0 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 42 clinical trials for acute lymphoblastic leukemia, of which 25 are open and 17 are closed. Of the trials that contain DEK status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 14 are phase 1 (7 open), 3 are phase 1/phase 2 (3 open), 20 are phase 2 (12 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 27 clinical trials for chronic myeloid leukemia, of which 16 are open and 11 are closed. Of the trials that contain DEK status and chronic myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 10 are phase 1 (6 open), 5 are phase 1/phase 2 (5 open), 10 are phase 2 (5 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 20 clinical trials for hodgkin lymphoma, of which 11 are open and 9 are closed. Of the trials that contain DEK status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 7 are phase 2 (5 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 17 clinical trials for non-hodgkin lymphoma, of which 10 are open and 7 are closed. Of the trials that contain DEK status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 7 are phase 2 (5 open) [4].

DEK is an inclusion criterion in 15 clinical trials for chronic myelomonocytic leukemia, of which 11 are open and 4 are closed. Of the trials that contain DEK status and chronic myelomonocytic leukemia as inclusion criteria, 6 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), and 6 are phase 2 (5 open) [4].

DEK is an inclusion criterion in 15 clinical trials for multiple myeloma, of which 10 are open and 5 are closed. Of the trials that contain DEK status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 14 clinical trials for acute biphenotypic leukemia, of which 7 are open and 7 are closed. Of the trials that contain DEK status and acute biphenotypic leukemia as inclusion criteria, 7 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (2 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 12 clinical trials for chronic lymphocytic leukemia, of which 8 are open and 4 are closed. Of the trials that contain DEK status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [4].

DEK is an inclusion criterion in 8 clinical trials for Burkitt lymphoma, of which 3 are open and 5 are closed. Of the trials that contain DEK status and Burkitt lymphoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 8 clinical trials for mantle cell lymphoma, of which 3 are open and 5 are closed. Of the trials that contain DEK status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 7 clinical trials for acute leukemia, of which 2 are open and 5 are closed. Of the trials that contain DEK status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 7 clinical trials for anaplastic large cell lymphoma, of which 3 are open and 4 are closed. Of the trials that contain DEK status and anaplastic large cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain DEK status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [4].

DEK is an inclusion criterion in 7 clinical trials for myeloproliferative neoplasm, of which 4 are open and 3 are closed. Of the trials that contain DEK status and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 6 clinical trials for follicular lymphoma, of which 2 are open and 4 are closed. Of the trials that contain DEK status and follicular lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 6 clinical trials for marginal zone lymphoma, of which 2 are open and 4 are closed. Of the trials that contain DEK status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 6 clinical trials for myelofibrosis, of which 2 are open and 4 are closed. Of the trials that contain DEK status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), and 2 are phase 2 (1 open) [4].

DEK is an inclusion criterion in 5 clinical trials for lymphoma, of which 3 are open and 2 are closed. Of the trials that contain DEK status and lymphoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

DEK is an inclusion criterion in 5 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 4 are open and 1 is closed. Of the trials that contain DEK status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [4].

DEK is an inclusion criterion in 5 clinical trials for secondary acute myeloid leukemia, of which 5 are open and 0 are closed. Of the trials that contain DEK status and secondary acute myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (2 open) [4].

DEK is an inclusion criterion in 5 clinical trials for small lymphocytic lymphoma, of which 2 are open and 3 are closed. Of the trials that contain DEK status and small lymphocytic lymphoma as inclusion criteria, 4 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

DEK is an inclusion criterion in 4 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain DEK status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [4].

DEK is an inclusion criterion in 4 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 3 are closed. Of the trials that contain DEK status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 1 is closed. Of the trials that contain DEK status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (2 open) [4].

DEK is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain DEK status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [4].

DEK is an inclusion criterion in 4 clinical trials for mixed phenotype acute leukemia, of which 3 are open and 1 is closed. Of the trials that contain DEK status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (2 open) [4].

DEK is an inclusion criterion in 4 clinical trials for prolymphocytic leukemia, of which 2 are open and 2 are closed. Of the trials that contain DEK status and prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 4 clinical trials for refractory anemia with excess blasts, of which 2 are open and 2 are closed. Of the trials that contain DEK status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (2 open) [4].

DEK is an inclusion criterion in 3 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain DEK status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

DEK is an inclusion criterion in 3 clinical trials for lymphoblastic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain DEK status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

DEK is an inclusion criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 0 are open and 3 are closed. Of the trials that contain DEK status and lymphoplasmacytic lymphoma as inclusion criteria, 2 are phase 2 (0 open) and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain DEK status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

DEK is an inclusion criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain DEK status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [4].

DEK is an inclusion criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain DEK status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

DEK is an inclusion criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain DEK status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

DEK is an inclusion criterion in 2 clinical trials for acute undifferentiated leukemia, of which 2 are open and 0 are closed. Of the trials that contain DEK status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

DEK is an inclusion criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain DEK status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

DEK is an inclusion criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain DEK status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [4].

DEK is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain DEK status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain DEK status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

DEK is an inclusion criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 0 are open and 2 are closed. Of the trials that contain DEK status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 2 are phase 2 (0 open) [4].

DEK is an inclusion criterion in 2 clinical trials for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 1 is closed. Of the trials that contain DEK status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 2 are phase 2 (1 open) [4].

DEK is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain DEK status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [4].

DEK is an inclusion criterion in 2 clinical trials for plasma cell leukemia, of which 0 are open and 2 are closed. Of the trials that contain DEK status and plasma cell leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [4].

DEK is an inclusion criterion in 2 clinical trials for refractory anemia, of which 1 is open and 1 is closed. Of the trials that contain DEK status and refractory anemia as inclusion criteria, 2 are phase 2 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for acute bilineal leukemia, of which 1 is open and 0 are closed. Of the trial that contains DEK status and acute bilineal leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for acute erythroid leukemia, of which 1 is open and 0 are closed. Of the trial that contains DEK status and acute erythroid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains DEK status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [4].

DEK is an inclusion criterion in 1 clinical trial for acute megakaryoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains DEK status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains DEK status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [4].

DEK is an inclusion criterion in 1 clinical trial for acute promyelocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains DEK status and acute promyelocytic leukemia as inclusion criteria, 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 1 clinical trial for adult acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains DEK status and adult acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains DEK status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

DEK is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains DEK status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for B-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains DEK status and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

DEK is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains DEK status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

DEK is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains DEK status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

DEK is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains DEK status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains DEK status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains DEK status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains DEK status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains DEK status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

DEK is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains DEK status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

DEK is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains DEK status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

DEK is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains DEK status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains DEK status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains DEK status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains DEK status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

DEK is an inclusion criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains DEK status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].

DEK is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains DEK status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains DEK status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains DEK status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

DEK is an inclusion criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains DEK status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains DEK status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

DEK is an inclusion criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains DEK status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains DEK status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

DEK is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains DEK status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

DEK is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains DEK status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (1 open) [4].